2026-12070NoticeWallet

Government Offers Ovarian Cancer Cell Line for License

Published Date: 6/16/2026

Notice

Summary

The National Cancer Institute is offering a special ovarian cancer cell line called A1847 for researchers to license and use. This cell line helps scientists study how ovarian cancer grows and find better treatments, especially for tough cases linked to BRCA1 gene problems. If you’re into cancer research, this is your chance to get a powerful tool starting now, with no big costs for licensing.

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

A1847 Ovarian Cancer Cell Line Offered

The National Cancer Institute is offering the A1847 human ovarian carcinoma cell line for nonexclusive license (NIH Reference E-137-2023-0). The line is BRCA1-deficient, was derived from a 50-year-old female, and is karyotypically characterized with modal number 68 and 3 marker chromosomes; it is offered as a research material/tool for screening drug candidates, identifying therapeutic targets, and generating animal models for metastatic ovarian cancer.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
6/16/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
National Institutes of Health
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register